Roaccutane Australia - English - Department of Health (Therapeutic Goods Administration)

roaccutane

roche products pty ltd - isotretinoin -

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 10 mL pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 10 ml pre-filled syringe

csl behring australia pty ltd - normal immunoglobulin, quantity: 2 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 5 mL pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 5 ml pre-filled syringe

csl behring australia pty ltd - normal immunoglobulin, quantity: 1 g - injection, solution - excipient ingredients: water for injections; proline; polysorbate 80 - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 5 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 5 ml vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 1 g - injection, solution - excipient ingredients: water for injections; proline; polysorbate 80 - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 10 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 10 ml vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 2 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 50 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 50 ml vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 10 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 20 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 20 ml vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 4 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

GAMMANORM normal immunoglobulin (human) 3300mg/20mL solution for intramuscular injection or subcutaneous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

gammanorm normal immunoglobulin (human) 3300mg/20ml solution for intramuscular injection or subcutaneous infusion vial

octapharma australia pty ltd - normal immunoglobulin, quantity: 3300 mg - injection, solution - excipient ingredients: tributyl phosphate; sodium chloride; water for injections; human immunoglobulin a; glycine; polysorbate 80; sodium acetate - replacement therapy in adults and children in primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency (cvid), severe combined immunodeficiencies, igg subclass deficiencies with recurrent infections. replacement therapy in myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.

GAMMANORM normal immunoglobulin (human) 1650mg/10mL solution for intramuscular injection or subcutaneous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

gammanorm normal immunoglobulin (human) 1650mg/10ml solution for intramuscular injection or subcutaneous infusion vial

octapharma australia pty ltd - normal immunoglobulin, quantity: 1650 mg - injection, solution - excipient ingredients: polysorbate 80; water for injections; glycine; tributyl phosphate; human immunoglobulin a; sodium acetate; sodium chloride - replacement therapy in adults and children in primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency (cvid), severe combined immunodeficiencies, igg subclass deficiencies with recurrent infections. replacement therapy in myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.

EVOGAM normal immunoglobulin (human) 16% w/v, 3.2g/20mL injection solution vial for subcutaneous use Australia - English - Department of Health (Therapeutic Goods Administration)

evogam normal immunoglobulin (human) 16% w/v, 3.2g/20ml injection solution vial for subcutaneous use

csl behring australia pty ltd - normal immunoglobulin, quantity: 3.2 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine; water for injections - evogam is indicated in adults and children for replacement therapy in: primary immunodeficiency disease (pid) and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.